药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Hydralazine
Bevantolol
Bevantolol may increase the bradycardic activities of Crizotinib.
Hydralazine
Dosulepin
The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Crizotinib.
Hydralazine
Fostemsavir
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Crizotinib.
Hydralazine
Gallopamil
The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Crizotinib.
Hydralazine
Celiprolol
The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Crizotinib.
Hydralazine
Inotersen
The risk or severity of QTc prolongation can be increased when Inotersen is combined with Crizotinib.
Hydralazine
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Crizotinib.
Hydralazine
Rufloxacin
The risk or severity of QTc prolongation can be increased when Rufloxacin is combined with Crizotinib.
Hydralazine
Lidoflazine
The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Crizotinib.
Hydralazine
Piromidic acid
The risk or severity of QTc prolongation can be increased when Piromidic acid is combined with Crizotinib.
Hydralazine
Lorajmine
The risk or severity of QTc prolongation can be increased when Lorajmine is combined with Crizotinib.
Hydralazine
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Crizotinib.
Hydralazine
Prajmaline
The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Crizotinib.
Hydralazine
Bencyclane
The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Crizotinib.
Hydralazine
Cibenzoline
The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Crizotinib.
Hydralazine
Cicletanine
The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Crizotinib.
Hydralazine
Pilsicainide
The risk or severity of QTc prolongation can be increased when Pilsicainide is combined with Crizotinib.
Hydralazine
Givinostat
The risk or severity of QTc prolongation can be increased when Givinostat is combined with Crizotinib.
Hydralazine
Temefos
The risk or severity of QTc prolongation can be increased when Temefos is combined with Crizotinib.
Hydralazine
Tetrahydropalmatine
The risk or severity of QTc prolongation can be increased when Tetrahydropalmatine is combined with Crizotinib.